Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment

Journal of Psychopharmacology

Volumn 26, Issue 9, 2012, Pages 1185-1193

  Chaudhry, Imran B ^a   Hallak, Jaime ^b   Husain, Nusrat ^a   Minhas, Fareed ^c   Stirling, John ^d   Richardson, Paul ^e   Dursun, Serdar ^f   Dunn, Graham ^a   Deakin, Bill ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c RAWALPINDI MEDICAL COLLEGE   (Pakistan)

^d MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^e SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

anti inflammatory; glutamate; minocycline; negative symptoms; neuroprotection; Schizophrenia

Indexed keywords

MINOCYCLINE; PLACEBO;

ADULT; ANOREXIA; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEGATIVE SYNDROME; PARKINSONISM; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SKIN DISCOLORATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; BRAZIL; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MINOCYCLINE; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PAKISTAN; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84864999825     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112444941     Document Type: Article

References (43)

1. Diagnostic and Statistical Manual of Mental Disorders. 2000 ) Diagnostic and Statistical Manual of Mental Disorders (Revised 4th ed. Text Revision). Washington, DC: APA. Washington, DC: APA ; 2000 :
2. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia- a double-blind, randomized, placebo-controlled trial. Biol Psychiat. 2008 ; 64: 361-368
3. Cahn W, van Haren NE, Hulshoff Pol HE, et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatr. 2006 ; 189: 381-382
4. Chaudhry IB, Husain N, Hallak J, et al. Preventing clinical deterioration in first episode psychosis: potential role of minocycline in neuroprotection. Neuropsychopharmacology. 2009 ; 34: S167
5. Chaudhry IB, Husain N, Khan S, et al. Amoxapine as an antipsychotic: comparative study versus haloperidol. J Clin Psychopharmacol. 2007 ; 27: 575-581
6. Choi SH, Lee DY, Chung ES, et al. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem. 2005 ; 95: 1755-1765
7. Crespo-Facorro B, Rodríguez-Sánchez JM, Pérez-Iglesias R, et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry. 2009 ; 70: 717-729
8. Deakin JFW, Slater P, Simpson MDC, et al. Frontal cortical and left temporal gluatamatergic dysfunction in schizophrenia. J Neurochem. 1989 ; 52: 1781-1786
9. Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010 ; 25: 97-107
10. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci. 2004 ; 25: 609-612
11. Duncan GE, Miyamoto S, Lieberman JA. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. J Pharmacol Exp Ther. 2003 ; 305: 999-1005
12. Eaton WW, Byrne M, Ewald H, et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006 ; 163: 521-528
13. Efron B, Tibshirani RJ An Introduction to the Bootstrap. London: Chapman and Hall ; 1993 :
14. Endicott J, Spitzer RL, Fleiss JL. The global assessment scale. Arch Gen Psychiatry. 1976 ; 33: 766-771
15. Everit BS, Pickles A Statistical Aspects of the Design and Analysis of Clinical Trials. London: Imperial College Press ; 1999 :
16. Foster R, Kandanearatchi A, Beasley C, et al. Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an inflammatory process?. Eur J Neurosci. 2006 ; 24: 3561-3566
17. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007 ; 6: 1045-1053
18. Guy W ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare ; 1976: 217-222.
19. Heyting A, Tolbroom JTBM, Essers JGA. Statistical handling of drop-outs in longitudinal clinical trials. Stat Med. 1992 ; 11: 2043-2061
20. Ho BC, Andreasen NC, Ziebell S, et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011 ; 68: 128-137
21. Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Annu Rev Med. 2007 ; 58: 49-61
22. Kay SR, Fisbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13: 261-276
23. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006 ; 31: 2033-2046
24. Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001 ; 58: 165-171
25. Krystal JH, D'Souza DC, Mathalon D, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003 ; 169: 215-233
26. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology. 2007 ; 69: 1404-1410
27. Lawrie SM, Whalley HC, Abukmeil SS, et al. Temporal lobe volume changes in people at high risk of schizophrenia with psychotic symptoms. Br J Psychiatr. 2002 ; 181: 138-143
28. Leeson VC, Barnes TR, Hutton SB, et al. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr Res. 2009 ; 107: 55-60
29. Levkovitz Y, Levi U, Braw Y, et al. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007 ; 18: 154-162
30. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010 ; 71: 138-149
31. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005 ; 62: 361-370
32. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand S. 1987 ; 76: 1-100
33. Little RJA, Rubin DB Statistical Analysis with Missing Data. 2002 ). Statistical Analysis with Missing Data (2nd Edition). Hoboken, NJ: John Wiley and Sons. Hoboken, NJ: John Wiley and Sons ; 2002 :
34. Miyaoka T, Yasukawa R, Yasuda H, et al. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol. 2008 ; 31: 287-292
35. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995 ; 52: 998-1007
36. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003 ; 361: 281-288
37. Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry. 2006 ; 11: 118-119
38. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008 ; 63: 801-808
39. Sorce S, Schiavone S, Tucci P, et al. The NADPH oxidase NOX2 controls glutamate release: a novel mechanism involved in psychosis-like ketamine responses. J Neurosci. 2010 ; 30: 11317-11325
40. Tarrier N, Lewis S, Haddock G, et al. Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. Br J Psychiatry. 2004 ; 184: 231-239
41. van Berckel BN. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008 ; 64: 820-822
42. van Haren NE, Hulshoff Pol HE, Schnack HG, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007 ; 32: 2057-2066
43. Zhang L, Shirayama Y, Iyo M, et al. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacol. 2010 ; 32: 2004-2010